Graybug Vision Inc
NASDAQ:GRAY 3:41:45 PM EDT
Products
Graybug Announces Pipeline Expansion, Current Cash Expected To Deliver Three Clinical Readouts In 2023
Published: 03/30/2022 11:33 GMT
Graybug Vision Inc (GRAY) - Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023.
Graybug Vision Inc - Phase 2 Trial With Optimized Formulation in Wet Amd Expected to Start in Q4 of 2022.
Graybug Vision Inc - New Programs for Retinitis Pigmentosa and Geographic Atrophy.
Graybug Vision Inc - Current Cash Expected to Fund Planned Operations Into Q4 of 2023.
Graybug Vision Inc - Phase 1 Trial in Glaucoma Expected to Commence in Q1 of 2023.
Graybug Vision Inc - Acquired Corneal Gene Therapy Program; Phase 1/2a Data Expected in Q4 of 2023.
Graybug Vision Inc - Phase 2 Trial With Optimized Formulation in Wet Amd Expected to Start in Q4 of 2022.
Graybug Vision Inc - New Programs for Retinitis Pigmentosa and Geographic Atrophy.
Graybug Vision Inc - Current Cash Expected to Fund Planned Operations Into Q4 of 2023.
Graybug Vision Inc - Phase 1 Trial in Glaucoma Expected to Commence in Q1 of 2023.
Graybug Vision Inc - Acquired Corneal Gene Therapy Program; Phase 1/2a Data Expected in Q4 of 2023.